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 Tetanus is a vaccine-
preventable disease that yearly causes 
a total of 309,000 deaths. Reports 
showed up to 1 million cases annually, 
mostly in underdeveloped countries. 
Clostridium tetani, the causative 
organism, is widespread in the faeces 
of domestic animals and humans, 
while spores of C. tetani are abundant 
in soil and in the environment 
surrounding the habitation of humans 
and animals. In developing countries, 
mortality rates are as high as 28 per 
100,000; in North America the rate is 
less than 0.1 per 100,000. 
Immunization programs clearly 
decreased neonatal tetanus deaths, 
and some recent evidence suggests 
progress in prevention throughout the 
World. Tetanus remains a great public 
health problem in developing countries 
such as Nigeria and it is associated 
with high mortality, but the 
understanding of the epidemiological 
aspects of this disease forms the basis 
of preventive strategies in any 
community. This paper reviewed the 
history, epidemiology and clinical 
diagnosis of tetanus and emphasized 
the current opinions in the 
management of tetanus outlining the 
various suggested treatment plans 
from experts in developing countries 




 Tetanus, an infective 
intoxication of the nervous system by 
clostridium tetani, is an ancient 
disease – as old as humans.  It is 
currently responsible for 1.2 million 
deaths in the developing world. 
Despite the widespread availability of a 
safe and effective vaccine against this 
disease, it remains a major health 
problem in developing countries, and 
also occurs in countries with good 
standard of medical practice. It is a 
disease associated with a high 
mortality rate and a major cause of 
death among neonates in developing 
African countries. It typically presents 
with trismus, difficulty in swallowing 
and more ominously difficulty in 
breathing or opisthotonus. The 
incidence of tetanus has been on 
gradual and continuous decline in 
developed countries due to organized 
mass tetanus immunization 
campaigns. The widespread use of 
tetanus toxoids (formulated as 
diphteria, whole-cell pertusis vaccine 
and tetanus toxoid-DPT) for infants 
and children, the use of both tetanus 
toxoids and tetanus immune globulin 
(TIG) for post-exposure prophylaxis in 
wound treatment and improved care 
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and management have contributed in 




 The word tetanus comes from 
the Greek tetanos, which is derived 
from the term teinein, meaning to 
stretch. Tetanus appears in military 
medical documents throughout the 
ages. In the Corpus Hippocraticum, 
Hippocrates (460-170BC) wrote that 
patients ‘die within 4 days or if they 
pass these they recover’. 
Cappadocium Aretans, the second 
century physician, described tetanus 
as ‘an awful disease, humble to watch’ 
and he concluded that’ the patient 
should die soon in order to end pain 
and wretched evil together with life’. 
Slapping infected dung on the 
umbilical cords of newborns (as part of 
ritualistic ceremonies) caused rampant 
tetanus neonatorum or trismus 
nascentium in the West Indies and in 
Africa. Osler's textbook describes the 
"eight days sickness" caused by 
umbilical sepsis, which killed 84 of 125 
children within a fortnight of birth in St 
Kilda, Scotland. During World War I, 
tetanus occurred in 1.47 per 1000 
British wounded and in 12.5 per 1000 
persons involved in the Peninsular 
campaign. Nicolaier discovered the 
anaerobic bacillus Clostridium tetani in 
1885 ending an era of ignorance of the 
causation. In 1889, Koch's pupil, 
Kitasato, obtained the bacillus of 
tetanus in pure culture and associated 
the disease to animals. The nineteenth 
and twentieth centuries however 
witnessed rapid and significant 
advances in the understanding of the 
pathophysiology of tetanus and this 
brought about the introduction of 
tetanus toxoid vaccination by Behring 





 Today, tetanus remains a great 
public health problem in developing 
African countries such as Nigeria.  It is 
an uncommon disease in most 
developed countries, where when it is 
reported it is associated with a high 
case fatality. Epidemiological studies 
have shown that tetanus affects all age 
groups but the predilection for the 
younger or older groups depends on 
whether the reports are from the 
developed or developing world.  There 
are conflicting reports as to the 
seasonal variation in the prevalence of 
tetanus.  While some workers report 
that it is more prevalent in the hot, dry 
season, others report that it is more 
common in the wet or humid seasons.  
The incidence of tetanus in Nigeria is 
higher in the hot dry season than in the 
wet but a few studies reported 
occurrence of more cases in the wet 
season.  It is believed that the reduced 
incidence during the rainy season is 
due to reduced outdoor activity, 
increased wearing of shoes and the 
washing away of animal waste that 
sometimes litters the streets.   On the 
other hand, the cases observed during 
the wet seasons were attributed to 
occupations of affected patients like 
farmers, manual laborers and traders 
as these groups of people are more 
prone to sustaining injuries during the 
wet season.  
 Several portals of entry have 
been documented, but in about 20% of 
cases, sources of infection may be 
unknown. Puncture wounds, 
circumcision, infected burns, post-
abortal sepsis, injection sites, guinea-
worn sores, road traffic accident 
wounds, otitis media, surgical 
procedures through contaminated 
gloves or poorly sterilized catgut 
sutures are some of the portals that 
have been described. 
 Tetanus continues to be a 
severe disease primarily of neonates 
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and older adults who are unvaccinated 
or inadequately vaccinated. In a study 
reported among a Danish population 
between 1978 and 19825, only 10% 
had history of previous complete 
vaccination and a similar report from 
the United State between 1989 and 
1990 showed that 11% had 
immunization prior to disease onset, 
and 31% lacked a history of tetanus 
vaccination. In the developed 
countries, earlier studies at the 
beginning of the twentieth century 
revealed a higher prevalence of 
tetanus in the lower age groups but 
more recently reports are showing a 
change with more cases being seen in 
the late adulthood and among the 
elderly people. This is attributed to the 
declining immune status of the elderly 
population. In the developing countries 
however, most cases are still in the 
younger age group although there are 
cases at the extremes of life, usually 
associated with higher mortality rates. 
In a study conducted in Benin City 
Nigeria, tetanus was more prevalent 
among the younger age group - a 
group commonly afflicted because of 
their susceptibility to injuries.  However 
in the developed countries where the 
tetanus vaccination programs have 
been very effective, most patients are 
>/=60 year.  This is related to declining 
immunity against tetanus as age 
increases. Data obtained from various 
national population-based serologic 
surveys indicate that the prevalence of 
immunity to tetanus is lower in older 
age groups, for example from >70 – 
80% among persons aged 6 -39 years 
declining to 28% among persons aged 
>/=70 years.  Studies have also shown 
that older adults lack protective levels 
of anti-tetanus antibodies and that 
elderly persons who reside in rural 
areas are more likely to be un-
immunized than elderly persons in 
urban areas.   
 The sex difference varies from 
one environment to the other, probably 
due to differences in cultural practice. 
Some earlier studies in Nigeria have 
reported a preponderance of males 
and this was thought to be due to 
susceptibility of men to injuries by 
virtue of their occupation, as more men 
are engaged in farming than women.  
However this occupational practice is 
not true for some areas of Nigeria, e.g. 
Niger Delta where more women 
engage in farming than men, hence 
more women are exposed to farming 
injuries.  This probably explained the 
higher female to male ratio in the study 
reported by Ogunrin et al as the Niger 
Delta area falls into the catchments 
area of the centre where this study 
was done. 
Majority of tetanus cases 
reported in Nigeria occurred after an 
acute injury mainly in the feet and leg 
and the injuries were frequently 
sustained through stepping on wood 
and cuts from cutlass.  This is similar 
to reports from the United States, 
where the most frequent wounds in 
tetanus patients were sustained by 
stepping on a nail. Chen et al in China 
and Simmonsen et al in Denmark have 
also reported the same trend.  These 
findings emphasized the place of 
wearing of shoes/boots or protective 
clothing by those who are in vulnerable 
positions by reason of their occupation 
as a mean of reducing the frequency 
of wounds sustained in such 
occupations.  
   The mortality of tetanus 
reported in the literature varies 
depending on the center where study 
was done.  The reports on mortality 
from tetanus in developing countries 
vary. In Nigeria, the mortality rate 
varies from 38% to 60%, depending on 
the infrastructure facilities and 
personnel at the reporting center.  A 
mortality rate of 26% was reported 
from a hospital-based study in Benin 
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City which is comparable to the rate of 
28% reported by Polish workers in 
1972 but much higher than reports 
from western countries.  Prognosis of 
tetanus varies according to duration of 
incubation, the speed with which signs 
become generalized, the severity of 
clinical presentation and access to the 
suitable treatment regimen. The 
average case-fatality ratio is 
approximately 50%. Mortality is 
caused by infection, respiratory, 




 Tetanus is classically divided 
into four clinical types: generalized, 
localized, cephalic, and neonatal. 
These are valuable diagnostic and 
prognostic distinctions, but they reflect 
host factors and the site of inoculation 
rather than differences in toxin action. 
Terms describing the initial stages of 
tetanus include incubation period (time 
from inoculation to the first symptom 
which is usually trismus) and period of 
onset (time from the first symptom to 
the first generalized spasm). The 
shorter these periods are the worse 
the prognosis. Various rating scales 
are available (see scale below – table 
1). Certain portals of entry (e.g., 
compound fractures) are associated 
with poorer prognoses. Tetanus may 
be particularly severe in narcotic 
addicts, for unknown reasons.  
 Generalized tetanus is the most 
commonly recognized form; it often 
begins with trismus (masseter rigidity, 
known as “lockjaw”) and a risus 
sardonicus (increased tone in the 
orbicularis oris). Dysphagia and 
abdominal rigidity may also be 
present. The generalized spasm 
resembles decorticate posturing and 
consists of opisthotonic posturing with 
flexion of the arms and extension of 
the legs. The patient does not lose 
consciousness and experiences 
severe pain during each spasm. The 
spasms often are triggered by sensory 
stimuli. During the spasm, the upper 
airway can be obstructed, or the 
diaphragm may participate in the 
general muscular contraction. Either of 
these compromises respiration and 
even the first of such spasm may be 
fatal. In the modern era of intensive 
care, however, the respiratory 
problems are easily managed, and 
autonomic dysfunction, usually 
occurring after several days of 
symptoms, has emerged as the 
leading cause of death. The illness can 
progress for about 2 weeks, reflecting 
the time required to complete the 
transport of toxin that is already intra-
axonal when antitoxin treatment is 
given. The severity of illness may be 
decreased by partial immunity. 
Recovery takes an additional month 
and is complete unless complications 
supervene. Lower motor neuron 
dysfunction may not be apparent until 
spasms remit, and recovery from this 
deficit in neuromuscular transmission 
may take additional weeks. Recurrent 
tetanus may occur if the patient does 
not receive active immunization, 
because the amount of toxin produced 
is inadequate to induce immunity.  
 Localized tetanus involves 
rigidity of the muscles associated with 
the site of spore inoculation. This may 
be mild and persistent and often 
resolves spontaneously. Lower motor 
neuron dysfunction (weakness and 
diminished muscle tone) is often 
present in the most involved muscle. 
This chronic form of the disease 
probably reflects partial immunity to 
tetanospasmin. However, localized 
tetanus is more commonly a prodrome 
of generalized tetanus, which occurs 
when enough toxin gains access to the 
central nervous system.  
 Cephalic tetanus is a special 
form of localized disease affecting the 
cranial nerve musculature. Although 
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earlier reports linked cephalic tetanus 
to a poor prognosis, more recent 
studies have revealed many milder 
cases. A lower motor neuron lesion, 
frequently producing facial nerve 
weakness, is often apparent. Extra-
ocular muscle involvement is 
occasionally noted.  
DIAGNOSIS 
 Tetanus is diagnosed by clinical 
observation and has a limited 
differential diagnosis. Laboratory 
testing cannot confirm or exclude the 
condition, and it is primarily useful for 
excluding intoxications that can mimic 
tetanus. Electromyographic studies are 
occasionally useful in questionable 
cases. Such testing becomes more 
important when no portal of entry is 
apparent. Antitetanus antibodies are 
undetectable in most tetanus patients, 
but many reports document the 
disease in patients with antibody levels 
above the commonly cited “protective” 
concentration of 0.01 IU/L. Rare 
patients apparently develop antibodies 
that are not protective.  
 Attempts to culture C. tetani 
from wounds are not useful in 
diagnosis, since (1) even carefully 
performed anaerobic cultures are 
frequently negative; (2) a positive 
culture does not indicate whether the 
organism contains the toxin-producing 
plasmid; and (3) a positive culture may 
be present without disease in patients 
with adequate immunity.  
 Strychnine poisoning, in which 
glycine is antagonized, is the only 
condition that truly mimics tetanus; 
toxicologic studies of serum and urine 
should be performed when tetanus is 
suspected, and tetanus should be 
considered even if strychnine 
poisoning appears likely. Because the 
initial treatments of tetanus and 
strychnine intoxication are similar, 
therapy is instituted before the assay 
results are available. Dystonic 
reactions to neuroleptic drugs or other 
central dopamine antagonists may be 
confused with the neck stiffness of 
tetanus, but the posture of patients 
with dystonic reactions almost always 
involves lateral head turning, which is 
rare in tetanus. Treatment with 
anticholinergic agents (benztropine or 
diphenhydramine) is rapidly effective 
against dystonic reactions. Dental 
infections can produce trismus, and 
should be sought, but they do not 
cause the other manifestations of 
tetanus.  
 
Table 1: ABLETT CLASSIFICATION OF SEVERITY OF TETANUS 
Grade Clinical features 
I Mild: mild to moderate trismus; general spasticity; no respiratory 
embarrassment; no spasms; little or no dysphagia. 
II Moderate: moderate trismus; well-marked rigidity; mild to moderate but short 
spasms; moderate respiratory embarrassment with an increased respiratory 
rate greater than 30; mild dysphagia. 
III Severe: severe trismus; generalized spasticity; reflex prolonged spasms; 
increased respiratory rate greater than 40; apnoeic spells; severe 
dysphagia; tachycardia greater than 120.
IV Very severe: grade III and violent autonomic disturbances involving the 
cardiovascular system. Severe hypertension and tachycardia alternating 
with relative hypotension and bradycardia, either of which may be 
persistent.  
A prognostic score has been proposed by a team from Senegal (Dakar, 1975), which 
can be established after the third day following the first clinical signs.  
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The prognosis will be bleaker as the clinical score increases.  
Number Prognostic factor 1 point 0 point 
1 Duration of 
incubation 
< 7 days ≥ 7 days or 
unknown 
2 Duration of patency < 2 days ≥ 2 days 
3 Entry point Ombilicus, uterus, burns, 
complex open fractures, 
surgical procedure, 
intramuscular injection 
Other or unknow 
point of entry 
4 Paroxysms Yes No 
5 Rectal temperature > 38.4°C ≤ 38.4°C 
6 Pulse 
- in adults 
- in newborns 
 
> 120 bpm 
> 150 bpm 
 
≤ 120 bpm 
≤ 150 bpm 
The disease progresses over 3 weeks on average. Disease may recur in survivors 
who have not been vaccinated, as the infection is not immunogenic.  
MANAGEMENT 
 The patient with tetanus 
requires simultaneous attention to 
several concerns. Attention to the 
airway and to ventilation is paramount 
at the time of presentation, but the 
other aspects of care, especially 
passive immunization, must be 
pursued as soon as the respiratory 
system is secure. The goals of therapy 
are to eliminate the source of toxin, 
neutralize unbound toxin and prevent 
or abort (as the case may be) muscle 
spasms, monitoring the patient's 
condition and providing support – 
especially respiratory support – until 
recovery. Table 1 presents a 
suggested management protocol. 
a. Eliminating the source of toxin: 
Antibiotic Therapy  
 Although of unproven value, 
antibiotic therapy is administered to 
eradicate vegetative cells – the source 
of toxin. The in vitro susceptibilities of 
C. tetani include metronidazole, 
penicillins, cephalosporins, imipenem, 
macrolides, and tetracycline. The use 
of penicillin (10 to 12 million units 
intravenously, given daily for 10 days) 
has been recommended, but 
metronidazole (500 mg every 6 h or 1 
g every 12 h) is preferred by some 
experts on the basis of this drug's 
excellent antimicrobial activity, a 
survival rate higher than that obtained 
with penicillin in one nonrandomized 
trial, and the absence of the GABA 
antagonistic activity seen with 
penicillin. A study comparing oral 
metronidazole with intramuscular 
penicillin showed a better survival rate, 
shorter hospitalization, and less 
progression of disease in the 
metronidazole group. Another 
prospective, open, non-randomised 
clinical trial was carried out to compare 
the efficacy of procaine penicillin with 
metronidazole in the treatment of 
moderate tetanus among 173 patients. 
Patients in the metronidazole group 
had a significantly lower mortality rate, 
a shorter stay in hospital, and an 
improved response to treatment. 
These results showed that 
metronidazole is more efficacious than 
penicillin in this respect. Clindamycin 
and erythromycin are also alternatives 
for the treatment of penicillin-allergic 
patients. Additional specific 
antimicrobial therapy should be given 
for active infection with other 
organisms. In patients with a deep 
wound, thorough debridement and 
toilet, and antibiotic therapy are critical 
to remove the source of toxin 
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production. If the wound itself requires 
surgical attention, this may be 
performed after spasms are controlled. 
However, the course of tetanus is not 
affected by wound débridement though 
a contrary observation was noted in a 
study that showed a 1.5 odds ratio in 
favour of patients who had wound 
debridement. Topical antibiotic 
application to the umbilical stump 
appears to reduce the risk of neonatal 
tetanus.  
b. Neutralizing unbound toxin  
 Antitoxin is used to neutralize 
circulating toxin and unbound toxin in 
the wound, antitoxin effectively lowers 
mortality, with an odds ratio of 4.56; 
toxin already bound to neural tissue is 
unaffected. Passive immunization with 
human tetanus immune globulin 
(HTIG) shortens the course of tetanus 
and may lessen its severity. Human 
tetanus immune globulin (TIG) is the 
preparation of choice and should be 
given promptly. The dose is 3000 to 
6000 units intramuscularly, usually in 
divided doses because the volume is 
large. The optimal dose is not known, 
however, and results from one study 
indicated that a 500-unit dose was as 
effective as higher doses. Pooled 
intravenous immunoglobulin may be 
an alternative to TIG, but the specific 
antitoxin concentration in this 
formulation is not standardized. There 
is no apparent advantage to intrathecal 
HTIG administration. Intrathecal 
(HTIG) has also been shown to be 
ineffective in neonatal tetanus. Pooled 
intravenous immune globulin has been 
proposed as an alternative to HTIG. It 
may be best to administer antitoxin 
before manipulating the wound; the 
value of injecting a dose proximal to 
the wound or infiltrating the wound is 
unclear. Additional doses are 
unnecessary because the half-life of 
antitoxin is long. Antibody does not 
penetrate the blood-brain barrier. 
Intrathecal administration should be 
considered experimental. Equine 
tetanus antitoxin (TAT) is not available 
in the United States but is used 
elsewhere especially in poor resource 
countries. It is cheaper than human 
antitoxin, but its half-life is shorter and 
its administration commonly elicits 
hypersensitivity and serum sickness. 
Active immunization must also be 
initiated after antitoxin. 
c. Control of Muscle spasms   
 Many agents, alone and in 
combination, have been used to treat 
the muscle spasms of tetanus, which 
are painful and can threaten ventilation 
by causing laryngospasm or sustained 
contraction of ventilatory muscles. The 
ideal therapeutic regimen would 
abolish spasmodic activity without 
causing oversedation and 
hypoventilation. Benzodiazepines have 
emerged as the mainstay of 
symptomatic therapy for tetanus. 
These drugs are GABA agonists and 
thereby indirectly antagonize the 
effects of the toxin. They do not 
restore glycinergic inhibition. 
Diazepam, a benzodiazepine and 
GABA agonist, is in wide use. The 
dose is titrated, and large doses (250 
mg/d) may be required. Lorazepam, 
with a longer duration of action, and 
midazolam, with a short half-life, are 
other options. Barbiturates and 
chlorpromazine are considered 
second-line agents and seem equally 
effective. Therapeutic paralysis with a 
non-depolarizing neuromuscular 
blocking agent and mechanical 
ventilation may be required for the 
treatment of spasms unresponsive to 
medication or spasms that threaten 
ventilation. Tetanus patients have 
unusually high tolerance for the 
sedating effect of these agents and 
commonly remain alert at doses 
normally expected to produce 
anaesthesia. However, prolonged 
paralysis after the discontinuation of 
therapy with such agents has been 
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described, and both the need for 
continued paralysis and the 
occurrence of complications should be 
assessed daily. After the symptoms of 
tetanus subside, these agents must be 
tapered over at least 2 weeks to 
prevent withdrawal effects. 
 Alternative agents include 
propofol, which is expensive, and 
dantrolene and baclofen, which are 
being investigated in the hope of 
shortening the period of therapeutic 
paralysis. Propofol infusion is also 
effective but very expensive, and the 
amount necessary to control 
symptoms may exceed the patient's 
tolerance of the lipid vehicle. 
Neuroleptic agents and barbiturates, 
previously used for tetanus, are inferior 
for this indication and should not be 
used. Magnesium infusion is rapidly 
emerging as a useful therapeutic 
technique in generalized tetanus. 
 The intravenous formulations of 
both diazepam and lorazepam contain 
propylene glycol; at the doses required 
to control generalized tetanus, this 
vehicle may produce lactic acidosis. 
Nasogastric delivery of these agents is 
possible but often discouraged 
because of risk of laryngospasm and 
some tetanus patients develop 
gastrointestinal motility disorders and 
do not absorb drugs well. Intravenous 
midazolam (5 to 15 mg/hour or more) 
is effective and does not contain 
propylene glycol, but it must be given 
as a continuous infusion because of its 
brief half-life. Rarely, tetanus cannot 
be adequately controlled with 
benzodiazepines alone; 
neuromuscular junction blockade is 
then indicated, with the caveat that 
sedation is still required for 
psychological reasons. All of the 
available drugs have side effects, 
including the potential for prolonged 
effects after the drug is discontinued. 
Vecuronium (by continuous infusion) 
or pancuronium (by intermittent 
injection) is an adequate choice. 
These agents should be stopped at 
least once daily to assess the patient's 
progress and to observe for possible 
complications. 
Electroencephalographic monitoring is 
a useful adjunct for this purpose. 
d. Monitoring the patient's 
condition and providing support 
– especially respiratory support 
– until recovery. 
 Tetanic spasms sometimes 
demand that the airway be secured 
before other lines of therapy are 
possible. Intubation or tracheostomy, 
with or without mechanical ventilation, 
may be required for hypoventilation 
due to oversedation or laryngospasm 
or for the avoidance of aspiration by 
patients with trismus, disordered 
swallowing, or dysphagia. The need 
for these procedures should be 
anticipated, and they should be 
undertaken electively and early. An 
orotracheal tube can be passed under 
sedation and neuromuscular junction 
blockade; a feeding tube should be 
placed at the same time. Please note 
that because the endotracheal tube 
can stimulate spasms, an early 
tracheostomy may be beneficial. 
e. Autonomic Dysfunction   
 The optimal therapy for 
sympathetic overactivity has not been 
defined. Autonomic dysfunction 
generally reflects excessive 
catecholamine release and may 
respond to combined α- and β-
adrenergic blockade with intravenous 
labetalol. Agents that have been 
considered include labetalol (an α- and 
β-adrenergic blocking agent that is 
recommended by some experts but 
that reportedly has caused sudden 
death), esmolol administered by 
continuous infusion (a beta blocker 
whose short half-life may be 
advantageous in the event of severe 
hypertension from unopposed α-
adrenergic activity), clonidine (a 
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central-acting antiadrenergic drug), 
and morphine sulphate. Parenteral 
magnesium sulfate and continuous 
spinal or epidural anesthesia have 
been used but may be more difficult to 
administer and monitor. The relative 
efficacy of these modalities has yet to 
be determined. Hypotension or 
bradycardia may require volume 
expansion, use of vasopressors or 
chronotropic agents, or pacemaker 
insertion. 
Other approaches to hypertension 
include morphine infusion, magnesium 
sulfate infusion, and epidural blockade 
of the renal nerves. Hypotension is 
less common; if present, it may require 
norepinephrine infusion. Myocardial 
dysfunction is also common and may 
represent a further reflection of 
catecholamine excess.  
Nutritional support should be started 
as soon as the patient is stable. The 
volume of enteral feeding needed to 
meet the exceptionally high caloric and 
protein requirements of these patients 
may exceed the capacity of the 
gastrointestinal system.  
 
Table II: SUGGESTED MANAGEMENT PROTOCOL FOR GENERALIZED 
TETANUS (modified by author to suit local management strategies) 
I. Diagnosis and stabilization: first hour after presentation 
A. Assess airway and ventilation. If necessary, perform endotracheal intubation using benzodiazepine 
sedation and neuromuscular blockade (e.g., vecuronium 0.1 mg/kg). This is not necessary in most 
cases. 
B. Obtain samples for antitoxin level, strychnine and dopamine antagonist assays, electrolytes, blood 
urea nitrogen, creatinine, creatine kinase, and urinary myoglobin determination.  
C. Determine the portal of entry, incubation period, period of onset, and immunization history.  
D. Administer benztropine (1–2 mg, intravenously) or diphenhydramine (50 mg, intravenously) to rule 
out a dystonic reaction to a dopamine blocking agent (if not sure of diagnosis). In most cases however 
the diagnosis is obvious. 
E. Administer a benzodiazepine intravenously (diazepam in 5-mg increments, or lorazepam in 2-mg 
increments) to control spasm and decrease rigidity. Initially, employ a dose that is adequate to produce 
sedation and minimize reflex spasms. If this dose compromises the airway or ventilation, intubate using 
a short-acting neuromuscular blocking agent. Transfer the patient to a quiet, darkened area of the 
intensive care unit.  
II. Early management phase: first 24 hours  
A. Administer human tetanus immunoglobulin (HTIG), 500 IU, intramuscularly; as an alternative, 
consider intravenous pooled immune globulin (see text). In some African countries including Nigeria, 
the equine anti-tetanus serum is used because it is cheap and readily available.   
B. At a different site, administer adsorbed tetanus toxoid such as tetanus-diphtheria vaccine (0.5 ml) or 
diphtheria-pertussis-tetanus vaccine (0.5 ml), as appropriate for age, intramuscularly. Adsorbed tetanus 
toxoid without diphtheria toxoid is available for patients with a history of reaction to diphtheria toxoid; 
otherwise, the correct combination for the patient's age should be employed. This is controversial as 
some experts believe active immunization should be commenced when the patient is more stable or 
prior to discharge from the hospital. This is to prevent the possible neutralizing effect of TIG on the 
tetanus toxoid.  
C. Begin metronidazole 500 mg, intravenously, every 6 h for 7–10 days. Alternatively intravenous 
penicillin may be given (ensure patient is not allergic to penicillin).  
D. Perform a tracheostomy after placement of an endotracheal tube and under neuromuscular 
blockade if spasms produce any degree of airway compromise.  
E. Débride wounds as indicated.  
F. Place a soft, small-bore nasal feeding tube or a central venous hyperalimentation catheter, and 
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begin feeding. Some physicians prefer to place patients on nothing per oral until spasms are controlled 
to avoid the risk of laryngospasm. Patients receiving total parental nutrition should be given parenteral 
H2 blockade or other gastric protection.  
G. Administer benzodiazepines as required to control spasms and produce sedation. If adequate 
control is not achieved, institute long-term neuromuscular blockade (e.g., vecuronium 6 to 8 mg/h); 
continue benzodiazepines for sedation with intermittent electroencephalographic monitoring to ensure 
somnolence. Neuromuscular junction blockade should be discontinued daily to assess the patient's 
physical examination and to decrease the possibility of excessive accumulation of the blocking agent.  
III. Intermediate management phase: next 2–3 wk  
A. Treat sympathetic hyperactivity with labetalol (0.25–1.0 mg/min as needed for blood pressure 
control) or morphine (0.5–1.0 mg/kg/h by continuous infusion; see text for other recommendations). 
Consider epidural blockade with a local anesthetic. Avoid diuretics for blood pressure control, because 
volume depletion worsens autonomic instability.  
B. If hypotension is present, initiate saline resuscitation. Place a pulmonary artery catheter and an 
arterial line and administer fluids, dopamine, or norepinephrine as indicated.  
C. Sustained bradycardia usually requires a pacemaker. Atropine or isoproterenol may be useful during 
pacemaker placement.  
D. Begin prophylactic heparin  
E. Use a flotation bed, if possible, to prevent skin breakdown and peroneal nerve palsies. Otherwise, 
ensure frequent turning and employ antirotation boots.  
F. Maintain benzodiazepines until neuromuscular blockade, if employed, has been terminated and the 
severity of spasms has diminished substantially. Then taper the benzodiazepine dose over 14–21 
days.  
G. Begin rehabilitation planning.  
IV. Convalescent stage: 2–6 weeks  
A. After spasms are no longer present, begin physical therapy. Many patients require supportive 
psychotherapy.  
B. Before discharge, administer another dose of tetanus-diphtheria vaccine or diphtheria-pertussis-
tetanus vaccine.  
C. Schedule a third dose of toxoid to be given 4 weeks after the second. 
Adapted from Bleck TP, Brauner JS. Tetanus. In: Scheld WM, Whitley RJ, Durack DT, eds. Infections of 
the Central Nervous System. 2nd ed. Philadelphia: Lippincott-Raven; 1997:629–653. 
Prognosis  
 The severity of spasms, 
duration of hospital stay, incubation 
period, onset time, immunization 
status and socio-economic 
background and the type of initial care 
are documented factors that affect 
mortality. The impact of pre-hospital 
care on outcome of tetanus infection 
needs to be further investigated. 
Prognosis has become progressively 
more favourable in developed 
countries. The mortality rate of mild 
and moderate tetanus in Western 
countries is presently about 6%; for 
severe tetanus, it may reach as high 
as 60%, even in expert centers. 
Among adults, age has very little effect 
on mortality, with octogenarians and 
nonagenarians faring as well as 
middle-aged patients. Tetanus 
survivors often have serious 
psychological problems related to the 
disease and its treatment that persist 
after recovery and may require 
psychotherapy.  
 The course of tetanus extends 
over 4 to 6 weeks, and patients may 
require ventilatory support for 3 weeks 
during this period. Increased tone and 
minor spasms can last for months, but 
recovery is usually complete. In a 
series of Italian patients, the mean 
length of stay was 40.3 days. In an 
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American series (CDC), previous 
vaccination status was directly related 
to severity of disease, with the case-
fatality ratio ranging from 6% for 
patients who had received one to two 
doses to 15% for patients who were 
unvaccinated. No deaths occurred 
among the 16 patients who previously 
had received three or more doses. 
PROPHYLAXIS 
Active Immunization  
 Tetanus is preventable in 
almost all patients, leading to its 
description as the “inexcusable 
disease.” A series of three monthly 
intramuscular injections of alum-
adsorbed tetanus toxoid provides 
almost complete immunity for at least 
5 years. Active protection should be 
maintained by administrating booster 
doses every 10 years. Patients 
recovering from tetanus should be 
actively immunized (see below) 
because immunity is not induced by 
the small amount of toxin that 
produces disease. 
 Although a full series of 
maternal immunizations is ideal, even 
one or two doses of tetanus toxoid 
confer substantial protection against 
neonatal tetanus In countries with 
incomplete immunization programs for 
children, all pregnant women should 
receive 2 doses of tetanus toxoid 
during the first pregnancy, with an 
interval of at least 1 month, and with 
the second dose at least 2 weeks 
before child birth. Application of topical 
antimicrobial agents to the umbilical 
cord stump markedly decreases the 
incidence of neonatal tetanus when 
maternal immunization is insufficient.  
 Some patients with humoral 
immune deficiencies may not respond 
adequately to toxoid injection; such 
patients should receive passive 
immunization for tetanus-prone injuries 
regardless of the period since the last 
booster injection.  
Prophylaxis in wound management 
 Although any wound may be 
inoculated with tetanus spores, some 
types of injury are more frequently 
associated with tetanus (tetanus 
prone). These include wounds that are 
contaminated with dirt, saliva, or feces; 
puncture wounds, including unsterile 
injections; missile injuries; burns; 
frostbite; avulsions; and crush injuries. 
Patients with these wounds who have 
not received adequate active 
immunization in the past 5 years, or in 
whom immunodeficiency is suspected, 
should receive passive immunization 
with Human TIG (250 to 500 IU, 
intramuscularly, regardless to the 
patient’s age) in addition to active 
immunization. If globulin is not 
available, animal antitoxin could be 
used at the dose of 1500 to 5000 IU. In 
that case, it is essential to avoid 
anaphylaxis by first injecting 0.02 ml of 
a 1/100 dilution in physiological saline 
solution intradermally, with a syringe 
containing adrenaline on hand. It is 
recommended to pretest with 1/1000 
solution if there has been prior animal 
serum exposure, with a similar saline 
solution injection as a negative control. 
If after 15-20 min there is a wheal with 
surrounding erythema, at least 3 mm 
larger than the control injection site, it 
is necessary to desensitize the 
individual.  
Neonatal tetanus: Measures aimed at 
preventing neonatal tetanus include 
maternal vaccination, even during 
pregnancy; efforts to increase the 
proportion of births that take place in 
the hospital; and the provision of 
training for nonmedical birth 
attendants. 
 Early human tetanus 
immunoglobulin (HTIG) 
administrations are associated with 
decreased mortality. Once the toxin is 
bound and internalized it will have no 
effect. When 3000 IU are administered 
intramuscularly, maximum 
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concentrations reach in 24-48 hr and 
approximately 0.1 IU/mL. Adequate 
concentrations of passive antitoxin that 
protect a human against tetanus are 
maintained for 10-15 days. Patients 
with tetanus also should actively be 
immunized through administration of 
adsorbed tetanus toxoid given 
intramuscularly at a site contralateral 
to the HTIG dosing. In a Korean study, 
vaccination with lower dose of DT 
(0.25 mL) induced an excellent 
immune response. In a monocentric, 
double-blind, randomized trial 
examining the safety and 
pharmacokinetic profile of a new, 
pasteurized, human tetanus 
immunoglobulin (P-HTIG)  and Td 
vaccine in combination in humans, the 
evolution of the tetanus antibody titers 
in the group that received P-HTIG 
alone and in the group that received P-
HTIG plus Td vaccine was similar until 
D3 to D7. In the P-HTIG plus placebo 
group, tetanus antibody titers rose to a 
maximum of 0.313 6 2.49 IU/ml after 
4.4 days; in the P-HTIG plus Td 
vaccine group, a maximum 
concentration of 15.2 6 2.42 IU/ml was 
reached 19 days postinjection. In both 
groups, 100% of the patients had 
seroprotective levels of tetanus 
antibodies (>0.01 IU/ml) 2 days 
following treatment. An anamnestic 
response to Td vaccine appeared 7 
days postimmunization. In conclusion, 
P-HTIG has a good safety and 
pharmacokinetic profile. Our results 
confirm that immunoglobulin should be 
associated with vaccine in the 
treatment of tetanus-prone wounds. 
Likewise, modelization of antibody 
titers clearly showed similar profiles in 
the two groups until the seventh day. 
These results demonstrate the 
absence of an early antitoxin response 
to the tetanus booster, similar to 
previous observations. The authors 
estimate that the formation of 
antibodies in response to vaccination 
occurs at about day 6. (An exact 
prediction cannot be made because of 
insufficient data between days 3 and 
7.) Thus, treatment of tetanus-prone 
wounds with immunoglobulin is crucial, 
especially in light of the fact that the 
incubation period of tetanus can be as 
short as 3 to 4 days.   
 Although data are conflicting, 
concurrent malarial infection may 
decrease the immune response to TT; 
however, malarial chemoprophylaxis 
may enhance the immune response. 
Malnutrition does not appear to affect 
immunogenicity; nevertheless, one 
study suggests that vitamin A 
deficiency is associated with an 
impaired immune response. Although 
it has been postulated that placental 
transfer of tetanus antibody is 
impaired in African women, a survey 
of the published literature suggests 
that this is not the case. Freezing TT 
has been shown to decrease its 
potency, but its impact on 
immunogenicity needs more 
evaluation. Conversely, poor storage 
conditions may reduce effectiveness: 
In the UK, a study found that safe 
storage of vaccine, and therefore 
guarantee of efficacy, is not occurring 
in the majority of A&E departments. 
Unnoticed failure of refrigerators could 
be exposing patients to the risk of 
tetanus infection. 
Table III: Management of tetanus in 
adult humans (African Study Group 
on Tetanus) 
It may be best to administer antitoxin 
before manipulating the wound. 
I) Human tetanus immune 
globulin (HTIG) 
 
3000-10 000 UI of HTIG by IM or IV 
route (40-150 UI/kg) according to most 
official recommendations 
500 IU IM may be as effective as 
larger doses according to some 
sources.  
Inject as soon as possible 
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Large doses may be fractioned and 
injected at multiple sites 
Site of injection proximal to the wound 
doesn’t appear to be preferable. 
No necessity for additional doses 
(because of prolonged half-life) 
DO NOT USE IM HTIG BY THE IV 
ROUTE (anaphylaxis) 
II) Antibiotics 
Intravenous Metronidazole 500 mg 
every 6 hours or 1 g every 12 hours for 
at least 10 days 
                    Or 
Penicillin 10-12 million units daily IV for 
10 days 
III) Benzodiazepine 
Diazepam intravenously by 5mg 
increment to control spasm  
Or 
Barbiturates / Chlorpromazine 
IV) Symptomatic treatment 
 
Rehydration 





Active immunization is needed 
because immunity is not induced by 
the small amount of toxin produced by 
the disease. 
GUIDELINES FOR THE 
MANAGEMENT OF TETANUS IN 
ADULT PATIENTS AT THE UBTH 
Prognosis of tetanus varies according 
to duration of incubation, the speed 
with which signs become generalized, 
the severity of clinical presentation and 
access to the suitable treatment 
regimen. The average case-fatality 
ratio is approximately 50%. Mortality is 
caused by infection, respiratory, 
cardiovascular or metabolic 
complications. 
A. Administer anti-tetanus 
serum/human tetanus 
immune globulin (HTIG) – 10, 
000 or 20, 000 units of ATS or 
3,000 – 10,000UI of HTIG by IM 
or IV route (40-150UI/Kg of 
HTIG). 500IU may be as 
effective as larger doses. For 
HTIG – inject as soon as 
possible. Large doses may be 
fractionated and injected at 
multiple sites. Site of injection 
proximal to the wound does not 
appear to be preferable. No 
necessity for additional doses 
(due to long half-life).  
DO NOT USE IM HTIG BY THE 
IV ROUTE (YOU WILL GET 
ANAPHYLAXIS) 
B. Give antibiotics – intravenous 
metronidazole 500mg every 6-8 
hours or 1gm 12 hourly for at 
least 10 days OR  Penicillin 10-
12million units in divided doses 
daily for 10 days. 
C. Give Benzodiazepine – 
diazepam intravenously by 5mg 
increment to control spasm. 
May add barbiturates and/or 
metocarbamol. In exceptional 
cases add chlorpromazine. 
D. Symptomatic treatment – 
rehydration with dextrose/saline 
infusion, nutritional support, 
mechanical ventilation in ICU 
and prophylactic heparin. 
E. Immunization – active 
immunization is needed 
because immunity is not 
induced by small amount of 
toxin produced by the organism. 
Give IM tetanus toxoid at 
discharge and repeat at 2 and 6 
weeks after the initial dose.  
From Neurology Unit, 
Department of Medicine, 
UBTH. Modified from the 




 Tetanus remains a clinical 
diagnosis because confirmatory 
laboratory tests are not available for 
routine use.  Isolation of organism from 
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wounds is neither sensitive nor 
specific, because anaerobic cultures of 
tissues or aspirates usually are not 
positive and the organism might be 
grown from wounds in the absence of 
clinical signs and symptoms of 
disease21,22.  The mortality associated 
with the infection is very high, 
especially in our environment where 
the lack of adequate facilities mitigates 
against comprehensive and optimal 
hospital in-patient care.  Our salvation 
therefore lies in preventive strategies 
implementation.  These include such 
measures as health education of the 
public on the need to protect 
themselves against sustaining wounds 
(especially by wearing protective 
shoes on the farm or the use of thick 
gloves for manual laborer), and the 
prompt treatment of every wound and 
the administration of tetanus toxoid 
and/ or tetanus immunoglobulin by a 
qualified health care giver.  Other 
measures include the establishment of 
tetanus care units in tertiary health 
institution, the inclusion of tetanus 
management as part of continuing 
medical education for all health care 
providers by their respective 
professional bodies and the zealous 
and dedicated implementation of the 
National program on Immunization on 
the part of the government. 
 
REFERENCES 
1. Abrutyn, E. Tetanus. Section 
143. Harrison's Principles of 
Internal Mediciene, 15th, ed. 
copyright. 2001 McGraw-Hill. 
 
2. Adams EB, Lawrence DR, 
Smith JWG. Tetanus. Oxford, 
Blackwell Scientific Publication, 
1969. Pg.1 
 
3. Adeuja AOG, Osuntokun BO. 
Tetanus in the adult Nigerian: a 
review of 503 patients.  East 
Afr. Med. J. 1971; 48: 653 – 
691. 
 
4. Adudu O P, Ogunrin O A, 
Adudu O G. Morbidity and 
Mortality patterns among 
neurological patients in the 
intensive care unit of a tertiary 
health facility. Ann. Afr. Med. 
2007; 6(4): 174-9. 
 
5. Afonja AO, Jaiyeola BO, 
Tunwashe L. Tetanus in Lagos. 
A review of 503 adult Nigerian 
patients. J. Trop Med Hyg. 
1973; 76:171 – 174. 
 
6. Alfery DD, Rauscher LA. 
Tetanus: a review. Crit. Care 
Med. 1979; 7: 176-81. 
 
7. Arogundade FA, Bello IS, 
Kuteyi EA, et al. Pattern of 
presentation and mortality in 
tetanus a 10 year retrospective 
review. Niger Postgrad Med J. 
2004; 11(3): 198-202.  
 
8. Bandele EO, Akinyanju MO, 
Bojuwoye BJ. An analysis of 
tetanus deaths in Lagos. J. Natl. 
Med. Assoc 1991; 83(1); 55 – 
58. 
 
9. Behring E. Knorr A. 
Tetanusantition fur die- 
Anwendung in der praxis. 
Dtsch.Med. Wschr. Monograph. 
1896.  
 
10. Bleck, TP. Clostridium tetani 
(Tetanus). Chapter 234. 
Mandell, Douglas and Bennett’s 
Principles and Practice of 
Infectious Diseases, 5th edition. 
Copyright. 2000, 1995, 1990, 
1985, 1979 by Churchill 
Livingstone. 
 
Journal of Postgraduate Medicine        O.A. Ogunrin 
 60  
 
11. Bytchenko D. Geographical 
distribution of tetanus in the 
world 1951 – 1960. A review of 
the problem. Bull World Health 
Organization. 1966; 34: 71- 
104. 
 
12. Caban J. Patients with tetanus 
from South Eastern Poland in 
material from the Clinic of 
Infectious Diseases in Krakow 
in the years 1993 – 1992. 
Przegl - Lek 1994: 51(11): 465-
7.  
 
13. Campbell J. Tetanus: a major 
killer still at large. Afri Health. 
2000; 22(4): 8-10. 
 
14. CDC. Tetanus – United States, 
1985 -1986. MMWR 1987; 36: 
477-81. 
 
15. CDC. Tetanus- United States, 
1987 and 1988. MMWR 1990; 
39-41. 
 
16. Chen FC, Sheen-Chen SM, 
Chou FF. High incidence of 
Tetanus in the middle aged and 
elderly. Chang Keng-I-Hsueh 
1990; 13(4):296-303. 
 
17. Edmondson RS, Flowers M W. 
Intensive care in tetanus 
management complication and 
mortality in 100 cases. Br. Med. 
J. 1979:1 1404-4. 
 
18. Gergen PJ, McQuillan GM, 
Kiely M, et al: A population – 
based serologic survey of 
immunity to tetanus in the 
United States N. Eng. J Med. 
1995; 332:761-766. 
 
19. Haberman E. Tetanus. In 
Vinker, P.J. Bruyn,G.W. Eds. 
Handbook of Clinical Neurology, 
Amsterdam, North Holland 
Publishing Company, 1978, 
Vol.3 pgs 491 – 547. 
 
20. Izurieta HS, Sutter RW, Strebel 
PM, et al: Tetanus Surveillance 
- United States, 1991-1994; 46 
(SS– 2): 15-691. 
 
21. Ogunrin AO, Unuigbe EI, 
Azubuike CO. Characteristics of 
tetanus cases seen over a ten 
year period in a tertiary health 
facility in Benin City, Nigeria. 
Ann Biomed Sci. 2006; 5(1&2): 
44-51. 
 
22. Ogunrin OA, Unuigbe EI. 
Tetanus: an analysis of the 
prognosticating factors of cases 
seen in a tertiary hospital in a 
developing African country 
between 1990 and 2000. Trop 
doct. 2004; 34(4): 240 – 41. 
 
23. Ojini FI, Danesi MA. Mortality of 
tetanus at the Lagos University 
Teaching Hospital, Nigeria. 
Trop Doct. 2005; 35(3): 178-81. 
 
24. Onwuekwe IO, Onyedum CC, 
Nwabueze AC. Experience with 
tetanus in a tertiary hospital in 
South East Nigeria. Niger J 
Med. 2008; 17(1): 50-52. 
 
25. Osuntokun BO. Perspectives in 
Tetanus: the past two decades. 
A symposium on ‘Recent 
Advances in Neuroscience’ 
Dokita 1990; 19(1): 74-78. 
 
26. PHLS. Communicable Diseases 
Surveillance Report. Br. Med. J 
1986; 293:680 -2. 
 
27. Prevots R, Sutter RW, Strebel 
PM, et al: Tetanus – United 
State 1989 – 1990 CDC MMWR 
1992; 41 (8); 1 – 9. 
 
Vol. 11 No. 1 December, 2009     Tetanus – A review of current concepts in management 
 61  
 
28. Rosmini F, Wirz M, Gentili G, et 
al: Year of birth, sex and 
residence as ‘determinants’ of 
tetanus incidence and immunity 
in Italy. Eur. J Epidemiology 
1987; 3 (4); 337 – 80. 
 
29. Sanya EO, Taiwo SS, Olarinoye 
JK, et al. A 12-year review of 
adult tetanus managed at the 
University College Hospital, 
Ibadan, Nigeria. Trop Doct 
2007; 37: 170-72. 
 
30. Simmonsen O, Block AV, Heron 
I. Epidemiology of Tetanus in 
Denmark 1920-1982, Scand. J 
Infect. Dis 1987; 19 (4); 437 – 
44. 
31. Unuigbe EI, Ogunrin AO. Does 
Pre-hospital care affect the 
outcome of tetanus patients? – 
an analysis of cases seen at a 
tertiary hospital in Nigeria. Nig 
Med Pract. 2003; 44(1): 19-21. 
 
32. Vidal J, Taberner JL, Plausi P, 
et al: The prevalence of tetanus 
antibodies in the adult 
population of Catalonia.  Med. 
Clin. Barc. 1992; 99(1): 6-8. 
 
33. Walsh JA. Establishing Health 
Priorities in the Developing 
World. New York, United 
Nations Development 
Programme, 1998, pg 15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
